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Abstract 
Introduction and objectives 
TTN gene truncating variants (TTNtv) are a frequent cause of dilated cardiomyopathy (DCM). However, there 
are discrepant data on the associated prognosis. Our objectives were to describe the prevalence of TTNtv in our 
cohort and to compare the clinical course with that described in the literature. 
 
Methods 
We included patients with DCM and genetic testing performed using next-generation sequencing. Through a 
systematic literature research, we collected information about carriers and affected relatives with TTNtv. We 
compared the cumulative percentage of affected carriers and the survival free of cardiovascular death. 
 
Results 
One hundred and ten DCM patients were evaluated. A total of 13 TTNtv distributed in 14 probands were 
identified (12.7%). We found a 21.4% prevalence in familial cases. No significant differences in the relation 
between age and clinical disease expression were identified. Survival free of cardiovascular death curves 
constructed from data in the literature seems not to overestimate the risk in our population. 
 
Conclusions 
The identification of TTNtv in patients with DCM is frequent and provides relevant information about the 
disease prognosis. The risk of cardiovascular death should not be underestimated. Age related penetrance need 
to be considered in the familial evaluation. 
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Introduction 
Titin gene truncating variants (TTNtv) are a frequent cause of dilated cardiomyopathy (DCM), 
occurring in 14–25% of cases [1,2]. Described penetrance of pathogenic TTNtv is age-dependent 
and varies among different cohorts [[2], [3], [4]]. There are limited and discrepant data in the 
literature on the associated prognosis. Case series have reported the highest prevalence 
of TTNtv among patients with severe disease [2,5]. However, in a clinical study of DCM probands 
and relatives, a milder course than in carriers of mutations in LMNA or negative genetic testing was 
observed [3]. 
Our objectives were to describe the prevalence of TTNtv in a cohort of DCM patients and to 
compare the clinical course with that described in the literature for TTNtv carriers. 
Methods 
Patient cohort 
From February 2014 to December 2018, 110 patients with DCM from A Coruña University 
Hospital were studied after informed consent with next-generation sequencing (NGS) panels 
including TTN and at least 80 other candidate genes. Clinical and genetic familial screenings were 
performed. The diagnosis of DCM was done following the European Society of Cardiology criteria 
[6]. DCM was considered familial when two or more individuals were affected, or in the presence 
of sudden unexplained death in a first-degree relative at <45 years of age [7]. 
The study protocol was approved by the Research Ethics Committee of A Coruña-Ferrol and 
followed the Helsinki declaration recommendations. 
Patients from literature 
We performed a comprehensive bibliographic search of studies published in PubMed (1 January 
1971 to Dec 2018) to collect available clinical information of families and individuals who 
carried TTNtv associated with DCM. The following search terms were used: “English”[Language] 
AND (“1900/01/01”[Date - Publication]: “2018/12/31” [Date - Publication]) AND (“dilated 
cardiomyopathy” OR “cardiomyopathy”) AND (“titin” OR “TTN”). 
The search was run on 10 of January of 2019 and retrieved 328 citations. All titles and abstracts 
of the articles were evaluated by two independent reviewers (L.M. and J.P.O.). After exclusion based 
on the title and abstract, a first selection of candidate articles was made. The full text of these articles 
was evaluated. We included affected and unaffected individuals following the same criteria used for 
our cases. 
Genetic studies 
Coding exons and intronic boundaries of at least 80 genes related to DCM were sequenced using 
the HiSeq 1500 platform (Illumina, San Diego, California, USA) following lllumina 
protocols. TTNtv were defined as those that were predicted to introduce a premature stop codon in 
the protein's sequence (nonsense or frameshift) or that could alter the splicing process according to 
the predictions of five software tools: MaxEntScan, Splice-Site Finder, HSF, NNSPLICE, and 
GeneSplicer, in any of the described protein isoforms. Pathogenicity of variants was classified 
according to current recommendations [8]. 
Survival analysis and disease penetrance 
Cardiovascular death was defined as the presence of sudden cardiac death, appropriate 
defibrillator shock, heart failure death, heart transplantation, death related to a cardiovascular 
intervention or stroke related death. For survival analysis we only considered carriers with 
pathogenic or likely pathogenic variants and available data. Survival free of cardiovascular death 
was estimated using the Kaplan-Meier method; factors were compared using the log-rank (Mantel-
Cox) test. Survival was calculated from birth. A two-sided p value < 0.05 was considered to indicate 
statistical significance. Analysis was performed using the R version 3.4.3 (The R Foundation for 
Statistical Computing Platform). 
Results 
Molecular findings 
A total of 13 TTNtv distributed in 14 probands were identified (Table 1), representing 12.7% of 
the 110 consecutive DCM patients who were sequenced. Nine of 42 familial cases (21.4%) carried 
a TTNtv compared to 5 of 68 sporadic patients (7.4%). The variant p.Glu3810* was identified in 2 
unrelated probands. A total of 61 probands´ relatives were identified. After informed consent and 
clinical study, targeted genetic testing was performed in 33 family members. Among relatives, 18 
mutations carriers were identified: 5 were clinically affected (27.8%) and 13 (72.2%) were 
considered not affected at a median age of 39.4 ± 19.3 years. Fifteen relatives were non-carriers. 
  
Table 1. Description of the identified TTN truncation variants in our cohort. 
 
Refseq transcript Protein (NP_003310.4) Chromosomic (NC_000002.11) Localization Exon  
number 
Exon PSI% GnomAD MAF% Family identifier Carriers  
(affected/unaffected) 
NM_00331  9.4 p.Thr300Aspfs*23 g.179664231_179664232insA Z disk 6 100 No 41,958 1 (1/0) 
NM_00331  9.4 p.Glu3810* g.179605443C>A I band 45 100 No 36,814, 3567 5 (3/2) 
NM_00331  9.4 p.Asn4176* g.179604349_179604350insA I band 45 100 No 36,815 2 (1/1) 
NM_00331  9.4 p.Arg4375* g.179602968G>A I band 46 100 No 25,921 2 (1/1) 
NM_00331  9.4 p.Arg8272* g.179474028G>A A band 101 100 No 41,933 3 (2/1) 
NM_00331  9.4 p.Tyr9697* g.179464342A>C A band 117 100 No 41,871 4 (2/2) 
NM_00331  9.4 p.Trp13407* g.179444509C>T A band 147 100 No 41,930 3 (2/1) 
NM_00331  9.4 p.Val16403Glufs*33 g.179434456delA A band 154 100 No 41,937 2 (1/1) 
NM_00331  9.4 p.Lys16797Argfs*25 g.179433275delT A band 154 100 No 41,932 4 (2/2) 
NM_00331  9.4 p.Tyr17457* g.179431293A>C A band 154 100 <0.001% 41,869 3 (1/2) 
NM_00331  9.4 p.Arg17841* g.179430143G>A A band 154 100 <0.001% 33,818 1 (1/0) 
NM_00331  9.4 p. Pro18608Glnfs*3 g.179427842_179427843delGTinsA A band 154 100 No 41,925 1 (1/0) 
NM_00331  9.4 p.Ala12453Serfs*14 :g.179449922_179449923insT A band 137 100 No 51,338 1 (1/0) 
Clinical characteristics of patients carrying TTNtv 
Seventy-five percent of the probands were male. Age at clinical diagnosis of the disease was 
highly variable both in our cohort (range from 16 to 69 years) and in the literature (range from 1 to 
78). The median age of diagnosis was 52 years old in our cohort and 43 in carriers from the literature 
(p = 0.13). The maximum incidence of clinical diagnosis was observed between ages 40 and 60 (Fig. 
1A). 
No significant differences in survival free of cardiovascular death, transplant or appropriate ICD 
discharge were observed between our cases with TTNtv and those from the bibliography (p = 0.17), 
although there was a trend toward a worse prognosis in our patients at advanced ages (Fig. 1B). 
In our cohort, 8 patients belonging to different families required a heart transplant. There were 2 
heart failure deaths in relatives with DCM and sudden cardiac death occurred in 4 patients belonging 
to the group of 51–60 years. In the group of carriers identified in the literature, heart failure deaths 
and transplants also predominated, but sudden cardiac death was frequent especially in younger 
patients (<40 years old). 
Discussion 
While studying 110 DCM patients we identified 14 TTNtv, 13 of them novel. The observed 
frequency is similar as in other published cohorts [2,5]. The majority of variants were located in the 
A-band region and all affected highly expressed exons, consistent with the findings published so far 
[5]. Penetrance increases with age, with a peak of incidence of new diagnosis between 40 and 
60 years. This stress the importance of a clinical follow-up until advances ages of unaffected carriers 
of TTNtv. 
The prognostic information obtained from survival curves constructed with data from the 
literature is concordant with the findings in our cohort and seems not to overestimate the risk of 
cardiovascular death in these patients. In fact, we found a trend toward a worse prognosis in our 
population that could be explained by the selection of the included patients. 
The most frequent causes of cardiovascular death were heart failure death and heart 
transplantation. However, sudden deaths were also frequent, both in our cohort and in the literature. 
Recent studies have observed that TTNtv carriers in non-ischemic DCM independently predicted 
early arrhythmias [9] and patients with TTNtv have shown an increased risk of developing 
ventricular arrhythmias that was independent of other covariates in patients with implanted 
defibrillators [10]. According to these data, DCM patients carrying TTNtv should not be considered 






Fig. 1. Comparison between accumulated percentage of affected carriers and cardiovascular death in patients from our cohort 




One of the limitations in our study was that clinical and genetic data on some of the relatives 
were not available and segregation could not be evaluated in several families. Also, referral and 
publication biases could have influenced the results toward the description of the more severe cases. 
In that sense, it is relevant to observe that the incidence of events in our cohort was higher than that 
obtained analysing data from the literature. 
Conclusions 
The identification of TTNtv in patients with DCM is frequent and provides relevant information 
about the disease prognosis. The risk of cardiovascular death and arrhythmias in these patients 
should not be underestimated. Age related penetrance need to be considered in the familial 
evaluation and follow up should be recommended in middle age unaffected carriers. 
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